Cash flow positive , no chance , costs are ridiculous at the moment ,£ 14.8 m loss this year and with FDA process starting , this will only increase . Their admin and R&D costs are very high .
The is the reason there will be another larger cash raise . Even if they achieve 43 hospitals , I see maybe £3.5m revenues for the year basing on 16 hospitals revenues of £1.2m
With FDA process to probably complete by end of 2025 , and that’s no delays or hiccups from FDA, sales in USA will begin mid 2026 . But when to these kind of things ever run in time .
Need to be bought out or a partner on board to make any decent returns in this which may eliminate cash issues needed for growth
RE: Full year results out in India30 May 2024 11:53
I be honest I do not how to value this but results are better than this time last year , but the share price is also 20% higher from the same period . Share us unloved , maybe because it is India and a coal consumer , but fundamentally it is in a stable
Sector in India and performing well with outgoing costs reducing and revenues all improving